Fresh Tracks Therapeutics (OTCPK:FRTX) - Aandelenkoers, Nieuws & Analyse

FRTX Overzicht aandelen

Fresh Tracks Therapeutics, Inc. heeft geen significante activiteiten. Meer informatie

FRTX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

De winst is de afgelopen 5 jaar met 5.8% per jaar gedaald

Heeft geen betekenisvolle marktkapitalisatie ( $4M )

De laatste financiële rapporten zijn ouder dan 6 maanden

Fresh Tracks Therapeutics, Inc. Concurrenten

Sunshine Biopharma

NasdaqCM:SBFM

US$4.7m

Scorpius Holdings

NYSEAM:SCPX

US$2.1m

Lipella Pharmaceuticals

NasdaqCM:LIPO

US$2.9m

Plus Therapeutics

NasdaqCM:PSTV

US$7.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Fresh Tracks Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	US$0.71
52 Week Hoogtepunt	US$1.03
52 Week Laag	US$0.55
Bèta	0.48
11 maand verandering	0.70%
3 maanden verandering	-15.88%
1 Jaar Verandering	-8.92%
33 jaar verandering	-95.00%
5 jaar verandering	-99.25%
Verandering sinds IPO	-99.66%

Recent nieuws en updates

Recent updates

Brickell Biotech changes name to Fresh Tracks Therapeutics

Sep 07

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Aug 11

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

Apr 27

Brickell Biotech's(NASDAQ:BBI) Share Price Is Down 16% Over The Past Year.

Jan 06

Brickell Biotech (BBI) Investor Presentation - Slideshow

Dec 02

Brickell Bio to launch sofpironium bromide gel, 5% in Japan on November 26

Nov 18

Rendement voor aandeelhouders

	FRTX	US Biotechs	US Markt
7D	0.4%	2.4%	2.2%
1Y	-8.9%	16.2%	31.7%

Rendement versus industrie: FRTX presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 16.2 % opleverde.

Rendement versus markt: FRTX presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.7 % opleverde.

Prijsvolatiliteit

Is FRTX's price volatile compared to industry and market?
FRTX volatility
FRTX Average Weekly Movement	6.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: FRTX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van FRTX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	4	Bert Marchio	ir.frtx.com

Fresh Tracks Therapeutics, Inc. heeft geen significante activiteiten. Voorheen hield het bedrijf zich bezig met de ontwikkeling van verschillende receptgeneesmiddelen voor de behandeling van auto-immuunziekten, ontstekingsziekten en andere slopende ziekten in de Verenigde Staten. Fresh Tracks Therapeutics, Inc. werd opgericht in 2009 en het hoofdkantoor is gevestigd in Boulder, Colorado.

Fresh Tracks Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Fresh Tracks Therapeutics zich tot de beurswaarde?
FRTX fundamentele statistieken
Marktkapitalisatie	US$4.27m
Inkomsten(TTM)	-US$5.69m
Inkomsten(TTM)	US$8.01m

0.5x

P/S-verhouding

-0.8x

Koers/Winstverhouding

Is FRTX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
FRTX resultatenrekening (TTM)
Inkomsten	US$8.01m
Kosten van inkomsten	US$3.18m
Brutowinst	US$4.82m
Overige uitgaven	US$10.52m
Inkomsten	-US$5.69m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.95
Brutomarge	60.25%
Nettowinstmarge	-71.12%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde FRTX op de lange termijn?

Bekijk historische prestaties en vergelijking

FRTX Overzicht aandelen

Risicoanalyse

Fresh Tracks Therapeutics, Inc. Concurrenten

NasdaqCM:SBFM

US$4.7m

NYSEAM:SCPX

US$2.1m

NasdaqCM:LIPO

US$2.9m

NasdaqCM:PSTV

US$7.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Price target increased to US$72.50

Consensus forecasts updated

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus estimates of losses per share improve by 25%

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Brickell Biotech changes name to Fresh Tracks Therapeutics

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Consensus revenue estimates increase by 26%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Brickell Biotech GAAP EPS of -$0.01 beats by $1.43, revenue of $4.32M beats by $1.18M

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech regains Nasdaq compliance for minimum bid price requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Consensus revenue estimates increase by 159%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus revenue estimates fall by 47%

Price target decreased to US$2.67

Full year 2021 earnings: EPS and revenues miss analyst expectations

Here's Why Brickell Biotech (NASDAQ:BBI) Must Use Its Cash Wisely

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought US$134k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Brickell Biotech Advances To Phase III As It Eyes Commercialization

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech completes patient enrollment in late-stage sweat disorder study

CEO & Director recently bought US$118k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021